Program Description
Transthyretin amyloidosis (ATTR) encompasses a spectrum of multisystemic disorders characterized by misfolded transthyretin (TTR) protein, which forms deposits in organs and tissues, disrupting normal function and structure. ATTR is highly heterogeneous, and the most common forms include ATTR-cardiomyopathy (CM) and ATTR-polyneuropathy (PN). ATTR-CM and ATTR-PN are distinct diseases, although a majority of TTR mutations lead to a mixed clinical phenotype where patients experience symptoms of both. Early recognition and clinical intervention using a multidisciplinary approach are paramount in mitigating the unique challenges in diagnosis and management as well as the impact of ATTR on patients' quality of life. Disease-modifying therapies have revolutionized the management of ATTR; however, optimizing treatment selection and dosing regimens requires pharmacists to evaluate patient- and disease-specific characteristics. This session will provide specialty and managed care pharmacists with an overview of the incidence, pathophysiology, risk factors, and clinical presentations associated with ATTR phenotypes as well as clinical recommendations regarding the use of current and emerging therapies.
Target audience: Health-system, managed care, and specialty pharmacists
Type of activity: Application
Release date: May 22, 2024
Expiration date: May 22, 2025
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the multisystem burden of disease in both hereditary and wild-type transthyretin amyloidosis (ATTR) and the importance of early recognition, diagnosis, and clinical intervention
- Identify the common clinical presentations associated with ATTR-cardiomyopathy (CM) and ATTR-polyneuropathy (PN) and the growing incidence of mixed phenotype
- Examine efficacy and safety data of FDA-approved therapies and current management strategies, including expert consensus, guidelines, and evidence for treatment of ATTR-CM, ATTR-PN, and mixed phenotype
- Determine effective measures to increase awareness about the different clinical presentations of ATTR phenotypes and make evidence-based recommendations to expand the use of disease-modifying therapies to improve clinical outcomes
Morie A. Gertz, MD, MACP
Chair, General Internal Medicine
Mayo Clinic
Rochester, Minnesota
Sabrina N. Livezey, PharmD, CSP
Clinical Pharmacist
Vanderbilt Specialty Pharmacy, Neurology
Vanderbilt University Medical Center
Nashville, Tennessee
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-148-H01-P. The activity is available for CE credit through May 22, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Morie A. Gertz, MD, MACP, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: Alnylam Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson, AstraZeneca
Sabrina N. Livezey, PharmD, CSP, has the following relevant financial relationship with a commercial interest to disclose:
Consultant (advisory board): Teva Medical
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms